Introduction

Tirzepatide and retatrutide are emerging multi-action peptide drugs that have garnered significant attention for their potent effects on weight loss and metabolic control. Tirzepatide (approved under the brand Mounjaro for diabetes) is a dual incretin mimetic, while retatrutide is an investigational triple-agonist. Both are being studied as treatments for obesity and type 2 diabetes mellitus (T2DM), aiming to improve upon the efficacy of existing glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide. This report reviews the latest peer-reviewed research on tirzepatide and retatrutide, focusing on their mechanisms of action, clinical trial outcomes (especially recent data from the past 1–2 years), efficacy in weight loss and metabolic health, safety profiles, regulatory status, and comparisons with semaglutide and other GLP-1 agonists.

Mechanism of Action of Tirzepatide and Retatrutide

Tirzepatide (Dual GIP/GLP-1 Agonist): Tirzepatide is often referred to as a "twincretin" because it combines agonism of two gut incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors[1][2]. By activating GIP and GLP-1 receptors, tirzepatide enhances insulin secretion and suppresses glucagon in a glucose-dependent manner, much like GLP-1 agonists, but with added effects from GIP signaling (Frias et al., 2021). Notably, GIP receptor activation may synergistically amplify GLP-1's metabolic effects and potentially mitigate some of GLP-1's side effects. Preclinical studies suggest that GIPR activation can reduce GLP-1–induced nausea and vomiting, improving tolerability[3]. Tirzepatide is a 39–amino acid synthetic peptide engineered with a fatty acid moiety to prolong its half-life (~5 days), allowing once-weekly dosing (Frias et al., 2021). In summary, tirzepatide's dual action leads to enhanced glucose-dependent insulin release, glucagon suppression (during hyperglycemia), delayed gastric emptying, and reduced appetite, thereby improving glycemic control and promoting weight loss (Jastreboff et al., 2022[4]).

Retatrutide (Triple GIP/GLP-1/Glucagon Agonist): Retatrutide is a single peptide that acts as an agonist at three receptors: GIP, GLP-1, and the glucagon receptor (GCG) (Sanyal et al., 2024). This triple-hormone agonism represents a novel mechanism aiming to harness the complementary benefits of all three gut hormones. Like tirzepatide, retatrutide stimulates insulin secretion and inhibits gastric emptying via GLP-1 and GIP receptors. In addition, by activating the glucagon receptor, retatrutide can increase energy expenditure and lipolysis. Glucagon receptor stimulation in the liver promotes hepatic fat oxidation and may improve fatty acid metabolism[5]. Indeed, the liver has minimal GLP-1/GIP receptors but is rich in glucagon receptors, suggesting the glucagon agonist component helps reduce liver fat and enhance metabolic rate (Sanyal et al., 2024). Retatrutide's peptide structure and fatty-acid conjugation confer a long half-life (~6 days) for weekly dosing[6][7]. Overall, retatrutide's mechanism combines potent appetite suppression and insulinotropic effects (via GLP-1/GIP) with increased energy expenditure and fat utilization (via glucagon receptor activation), a pharmacologic profile that has yielded unprecedented weight loss in early trials (Jastreboff et al., 2023).

Clinical Trial Outcomes and Latest Data

Tirzepatide: Key Clinical Trials

Tirzepatide has been evaluated in multiple Phase 3 trials, primarily the SURPASS series for type 2 diabetes and the SURMOUNT trials for obesity. In patients with T2DM, tirzepatide demonstrated remarkable glycemic efficacy and weight reduction. For example, the SURPASS-2 trial (Frías et al., 2021) compared tirzepatide to semaglutide in adults with T2DM inadequately controlled on metformin. Tirzepatide (5, 10, and 15 mg weekly) achieved HbA_1c reductions of roughly 2.0%–2.3%, significantly greater than the ~1.8% reduction with semaglutide 1 mg[4]. Tirzepatide also induced superior weight loss: by 40 weeks, patients on tirzepatide 15 mg lost on average 11.0 kg more body weight than baseline, versus about 5.5 kg with semaglutide (an incremental ~5.5 kg advantage)[8]. All doses of tirzepatide were statistically superior to semaglutide for both A1c and weight endpoints (Frías et al., 2021). These findings established tirzepatide's efficacy in diabetes management, with a substantial proportion of patients reaching glycemic targets (HbA_1c <7% or even <5.7%) and losing clinically meaningful weight.

In obesity without diabetes, the SURMOUNT-1 trial (Jastreboff et al., 2022) tested weekly tirzepatide at 5, 10, or 15 mg versus placebo in adults with obesity (BMI ≥30). The results, published in NEJM, were groundbreaking: at 72 weeks, mean weight reductions were –15.0% of initial body weight on 5 mg, –19.5% on 10 mg, and –20.9% on 15 mg, compared to only –3.1% with placebo[9]. Over half of those on 10 mg or 15 mg lost at least 20% of their body weight, a magnitude previously seen only with bariatric surgery[10]. Additionally, tirzepatide improved numerous metabolic parameters — waist circumference, blood pressure, lipid levels, and glycemic measures all moved in a favorable direction relative to placebo[11]. Notably, quality of life scores also improved with the weight loss. These outcomes confirmed tirzepatide's enormous potential as an anti-obesity therapy (Jastreboff et al., 2022). A follow-up SURMOUNT-2 trial in obese patients with diabetes similarly showed robust weight loss (~15% or more) alongside improved glycemic control, although results were slightly attenuated compared to metabolically healthy participants (a common pattern when obesity pharmacotherapies are tested in T2DM) (Rosenstock et al., 2022). Furthermore, extension studies indicate tirzepatide's effects can be durable: a recent 3-year data readout reported sustained weight reduction (~23% from baseline on 15 mg) with continued treatment, along with a significant delay in progression from prediabetes to diabetes (though this longer-term data is pending full publication). Overall, tirzepatide's clinical trial program demonstrates unprecedented efficacy in both glycemic lowering and weight loss, supporting its use in both diabetes and obesity management[12][8].

Retatrutide: Key Clinical Trials

Retatrutide is newer in development, and its notable results come from Phase 2 trials completed in the last two years. The most prominent is a 48-week Phase 2 trial in obesity, reported by Jastreboff et al. (2023). In this trial, 338 adults with obesity (BMI ~35, without diabetes) were randomized to various retatrutide dose-escalation regimens (ranging from 1 mg up to 12 mg weekly) or placebo (Jastreboff et al., 2023). The weight loss achieved was striking and dose-dependent. By week 48, retatrutide 12 mg weekly led to a mean weight reduction of 24.2% of baseline body weight, compared to a 2.1% loss in the placebo group[13]. Even lower doses showed substantial effect (−17.1% at 4 mg and −22.8% at 8 mg)[13]. In absolute terms, patients on 12 mg lost approximately 23–25 kg on average over 48 weeks. Moreover, 75–83% of participants on the top doses (8 mg or 12 mg) lost at least 15% of body weight, an efficacy notably exceeding that of currently approved agents in similar time frames[14]. It was observed that weight loss had not plateaued by 48 weeks at the highest dose, suggesting that longer treatment might yield even greater reductions (though this will need confirmation in Phase 3 trials). Alongside weight loss, retatrutide treatment improved metabolic health markers: fasting glucose and blood pressure decreased, and there were beneficial changes in cholesterol and liver enzyme levels in treated groups (Jastreboff et al., 2023; Sanyal et al., 2024).

Patients with type 2 diabetes have also been studied. Rosenstock et al. (2023) conducted a Phase 2 trial in T2DM where retatrutide (at maintenance doses of 4 mg, 8 mg, or 12 mg) was compared against placebo and an active comparator (the GLP-1 agonist dulaglutide 1.5 mg) over 36 weeks. By 24 weeks, HbA_1c reductions with retatrutide ranged from –1.3% (4 mg) up to –2.0% (12 mg), versus –1.41% with dulaglutide and ~0% with placebo[15]. The higher retatrutide doses clearly outperformed the standard GLP-1 agonist in glucose-lowering (p < 0.01 for 8 mg and 12 mg vs. dulaglutide) (Rosenstock et al., 2023). At 36 weeks, retatrutide's weight loss in T2DM was also impressive: the 12 mg group had lost about 16.9% of body weight, compared to ~2% with dulaglutide and 3% with placebo[16]. This degree of weight reduction in diabetes is remarkable (by contrast, in prior trials semaglutide 1 mg yields ~5–7% weight loss in T2DM, and even higher-dose semaglutide 2.4 mg gives ~10–12% in diabetics). These data underscore that retatrutide can substantially improve both glycemic control and body weight in patients with diabetes, surpassing the effects of current single-hormone therapies (Rosenstock et al., 2023).

Beyond weight and glucose endpoints, retatrutide may confer specific organ benefits due to its multi-receptor action. Notably, a sub-study of the obesity trial examined patients with nonalcoholic fatty liver disease. Over 48 weeks, retatrutide led to profound reductions in liver fat content – for instance, the 12 mg dose reduced liver fat by ~86% relative to baseline, and nearly all patients on 8–12 mg achieved resolution of steatosis (liver fat <5%)[17][18]. This suggests a potential role for retatrutide in treating metabolic dysfunction-associated steatotic liver disease (MASLD/NASH), an important obesity-related comorbidity (Sanyal et al., 2024). Improvements in ALT levels and liver fibrosis markers were also observed. Additionally, animal studies indicate retatrutide may ameliorate diabetic kidney disease parameters more effectively than GLP-1 alone (Ma et al., 2024). These findings are at the cutting edge of metabolic research and are being explored further.

Looking ahead, Phase 3 trials (the TRIUMPH program) for retatrutide are currently underway. TRIUMPH-1 and -2 will evaluate long-term weight outcomes in obese patients with and without diabetes, respectively, and are expected to run through 2025–2026 (Katsi et al., 2025). There are also dedicated Phase 3 studies examining cardiovascular outcomes and specific subpopulations (e.g. patients with obesity and osteoarthritis or obstructive sleep apnea). Until those are completed, retatrutide remains an investigational agent, but its Phase 2 results have set a new benchmark for anti-obesity efficacy.

Efficacy for Weight Loss and Metabolic Health

Weight Loss: Both tirzepatide and retatrutide have demonstrated exceptional weight loss efficacy, outperforming traditional GLP-1 agonists. In obesity trials, tirzepatide enabled roughly 15–21% body weight reduction over 72 weeks (at doses up to 15 mg) (Jastreboff et al., 2022), while semaglutide 2.4 mg (Wegovy) produces about a 15% reduction over a similar period (Wilding et al., 2021[19]). Retatrutide, even earlier in development, has shown ~22–24% weight loss in just 48 weeks at its highest doses (Jastreboff et al., 2023), indicating the potential to reach or exceed a 25–30% reduction with longer therapy. Such magnitude rivals what is typically achieved with bariatric surgery, marking a paradigm shift in medical obesity treatment. Importantly, substantial percentages of patients on these drugs achieve ≥5%, ≥10%, or ≥15% weight loss, thresholds associated with clinically significant improvements in health. For example, over 90% of those on retatrutide 8–12 mg lost ≥10%, and 75–83% lost ≥15% by 48 weeks[14]. Tirzepatide similarly had over 50% of patients losing ≥20% at top dose by 72 weeks[10]. These results underscore that a majority of patients can attain double-digit weight loss with these medications – a striking contrast to older pharmacotherapy where 5–10% was considered a success.

Metabolic Health Improvements: Beyond weight reduction, both agents confer broad metabolic benefits. In individuals with obesity without diabetes, tirzepatide and retatrutide have been shown to improve fasting glucose, fasting insulin levels, blood pressure, and lipid profiles compared to placebo (Jastreboff et al., 2022; Jastreboff et al., 2023). The weight loss itself contributes to many of these improvements, but there may also be direct drug effects (e.g. GLP-1 agonism is known to lower systolic blood pressure independent of weight). In tirzepatide's SURMOUNT-1 trial, treatment led to significant reductions in triglycerides, LDL cholesterol, and C-reactive protein, and increased HDL cholesterol, reflecting an overall improvement in cardiometabolic risk factor profile (Jastreboff et al., 2022). Measures of insulin resistance (HOMA-IR) also improved markedly with tirzepatide relative to placebo, even among non-diabetic subjects, indicating enhanced insulin sensitivity[11]. Similarly, retatrutide's Phase 2 data showed improvements in metabolic biomarkers such as ALT (linked to liver fat reduction), adiponectin, and liver fibrosis scores (Sanyal et al., 2024). The resolution of fatty liver disease observed in a high percentage of retatrutide-treated patients is particularly noteworthy, as NAFLD/MASLD has lacked effective pharmacotherapy to date (Sanyal et al., 2024[17]).

In patients with type 2 diabetes, these drugs greatly improve glycemic control, often eliminating the need for additional diabetes medications. Tirzepatide 15 mg can lower HbA_1c by around 2.0–2.5 percentage points from baseline (Frías et al., 2021), which is on par with potent insulin therapy – yet with the beneficial side effect of weight loss rather than weight gain. In fact, many tirzepatide-treated patients in trials were able to reduce or discontinue insulin and other hypoglycemic agents while maintaining excellent glycemic control (Frías et al., 2021). Retatrutide likewise showed ~2.0% reductions in HbA_1c at top dose by 24 weeks, bringing a majority of participants to non-diabetic glucose levels (Rosenstock et al., 2023). Both drugs have exhibited a notable ability to lower postprandial glucose excursions and even improve beta-cell function over time, likely due to giving the pancreas a restorative break from chronic hyperglycemia (Drucker, 2022). Another metabolic benefit observed with incretin-based therapies is blood pressure reduction – in trials, tirzepatide lowered systolic BP by ~5–6 mmHg more than placebo (and even a few mmHg more than semaglutide in SURPASS-2), partly via weight loss and partly via direct vasodilatory effects of GLP-1 (Jastreboff et al., 2022; Frías et al., 2021). Heart rate tends to increase slightly (a known GLP-1 class effect), but changes are modest (see Safety section).

A crucial point is that weight loss itself drives many metabolic improvements, and the amount of weight lost with tirzepatide or retatrutide often far exceeds the threshold needed for clinical benefit. For instance, losing ≥10% of body weight can lead to remission of T2DM or hypertension in many patients; with these drugs, 70–90% of treated patients reach that level of weight loss (Wilding et al., 2021[20][21]; Jastreboff et al., 2022). Furthermore, emerging evidence suggests that tirzepatide may reduce cardiovascular events. A large outcomes trial (SURPASS-CVOT) is ongoing to assess tirzepatide's impact on heart attack, stroke, and cardiovascular death in people with diabetes. However, a recent post-hoc analysis and real-world study indicated tirzepatide was associated with lower rates of major adverse cardiovascular events compared to GLP-1 agonists (Wang et al., 2023; Sattar et al., 2022), echoing the proven heart benefits of GLP-1 RAs like semaglutide. In summary, the efficacy profile of these drugs is multifaceted: they produce weight loss on the order of 15–25%, dramatically improve glycemic control, and favorably modulate risk factors for cardiovascular and metabolic diseases. This comprehensive efficacy sets them apart from earlier therapies and has generated excitement about disease-modifying potential in obesity, diabetes, and related conditions.

Safety Profiles and Side Effects

Common Adverse Effects: The safety profiles of tirzepatide and retatrutide are largely similar to those of other incretin-based therapies, with gastrointestinal (GI) symptoms being the most frequent side effects. In clinical trials, the majority of patients on either drug experienced at least one GI-related event, typically nausea, vomiting, diarrhea, or constipation (Jastreboff et al., 2022; Jastreboff et al., 2023). These effects were usually mild to moderate in severity and tended to occur during the initial dose-escalation phase[22][23]. Importantly, slower uptitration of the dose can improve tolerability. For example, in the retatrutide Phase 2 trial, investigators found that starting at 2 mg and gradually increasing to 8 or 12 mg mitigated GI symptoms compared to a faster escalation starting at 4 mg[24]. Nevertheless, dose-dependent GI effects were evident: higher doses caused more nausea and vomiting. Some patients cannot tolerate the full doses due to these symptoms.

Discontinuation rates due to adverse events provide perspective: In SURMOUNT-1, discontinuations for adverse events were 4–7% in the tirzepatide arms vs ~2.6% for placebo[25]. Similarly, with retatrutide up to 12 mg, about 5–10% of patients discontinued due to side effects, mostly GI (Jastreboff et al., 2023). These dropout rates, while higher than placebo, are not prohibitive and are comparable to those observed with high-dose semaglutide (4–5% discontinuation for GI effects[21] on semaglutide 2.4 mg). This suggests that with careful management (dose titration, symptomatic treatment), the majority of patients can remain on therapy. Notably, the inclusion of GIP agonism in tirzepatide was hypothesized to reduce nausea (as GIP can have anti-emetic effects); some trials did report slightly lower nausea incidence with tirzepatide 15 mg vs semaglutide 1 mg (Frías et al., 2021), but GI side effects still occur and need monitoring.

Beyond the gut, systemic side effects have been relatively mild. Neither tirzepatide nor retatrutide has shown significant organ-specific toxicity in trials to date. Transient increases in heart rate have been observed, a class effect of GLP-1 agonists likely due to sympathetic activation. In the retatrutide obesity trial, heart rate rose by an average ~5 beats per minute at mid-treatment, then partially subsided later despite continued therapy[26]. This is similar to semaglutide's heart rate profile. The clinical significance of this is unclear, but heart rate should be monitored in patients with cardiac conditions. Small elevations in pancreatic enzymes (amylase, lipase) are sometimes seen, as with all incretins, but these are typically asymptomatic and not accompanied by pancreatitis in trials (no increase in pancreatitis incidence has been definitively shown for GLP-1/GIP therapies in these studies).

One difference with retatrutide's triple-agonist action is the potential for effects related to glucagon receptor stimulation. Glucagon can raise hepatic amino-transferases and mobilize glucose; however, in trials retatrutide actually led to lower ALT and improved glycemia (due to weight loss and insulin sensitization dominating). A few patients on retatrutide reported injection-site reactions (erythema or itching) and a rare side effect noted was cutaneous hypersensitivity (hyperesthesia), though this was uncommon (Katsi et al., 2025). There were no signals of concerning cardiovascular adverse events; in fact, blood pressure generally decreased with treatment due to weight loss.

Safety Precautions: As with other incretin mimetics, tirzepatide and retatrutide carry class warnings. These include a contraindication in patients with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, because chronic GLP-1 receptor stimulation caused thyroid C-cell tumors in rodent studies (a precautionary warning; human relevance is unproven). Thus far, no thyroid cancers have been attributed to these drugs in human trials, but the theoretical risk remains. Patients should also be monitored for signs of pancreatitis, another theoretical risk (though large trials of GLP-1 RAs have not shown a significant pancreatitis signal, it is listed as a potential rare adverse event). Gastrointestinal side effects can predispose to dehydration, so patients should maintain hydration if they experience prolonged vomiting/diarrhea. Gallbladder-related events (gallstones) have been noted with GLP-1 agonists due to rapid weight loss; similarly, significant weight loss on tirzepatide/retatrutide may increase risk of gallstones in some patients, so abdominal symptoms should be evaluated.

In summary, the safety profile of tirzepatide and retatrutide appears favorable and in line with GLP-1 class medications. The main side effects are manageable GI symptoms. The risk-benefit tilts positive given the magnitude of benefits. Ongoing long-term trials will continue to assess safety, but so far no unexpected safety concerns have emerged with either drug (Jastreboff et al., 2022; Rosenstock et al., 2023). Patient education and gradual dose escalation are key to tolerability.

Regulatory Status and Recent Approvals

Tirzepatide: Tirzepatide was first approved by the U.S. Food and Drug Administration (FDA) in May 2022 for the treatment of type 2 diabetes, under the brand name Mounjaro (Eli Lilly) (Corrao et al., 2024). It has since been approved for T2DM in a number of other regions (for instance, the European Medicines Agency authorized it in 2022 as well). Given the impressive obesity trial results, Lilly pursued approval for a second indication: chronic weight management in adults with obesity. In late 2023, tirzepatide was approved by the FDA for obesity treatment (for patients with BMI ≥30, or ≥27 with weight-related comorbidities) (Corrao et al., 2024). The obesity indication is marketed under the name Zepbound in the U.S. (essentially the same medication/dose as Mounjaro, but indicated for weight loss). This made tirzepatide the first dual-incretin agonist approved for weight management. As of 2025, regulatory approvals for obesity are expanding globally; tirzepatide is under review by EMA and other agencies for that indication. The drug has also been fast-tracked in some regions for obesity given the high unmet medical need. With two approved indications, tirzepatide is expected to see widespread use in the coming years in endocrinology and obesity medicine.

Retatrutide: Retatrutide is currently in Phase 3 development and is not yet approved for clinical use. Eli Lilly, the sponsor, initiated multiple Phase 3 trials (TRIUMPH series) in 2023 following the successful Phase 2 results. These trials will enroll thousands of patients with obesity (with and without diabetes) to confirm efficacy and safety over longer durations (68–88 weeks of treatment) (Katsi et al., 2025). The expected completion for the first pivotal trial is in 2025–2026, after which Lilly may file for regulatory approval if outcomes are positive. The FDA has recognized the therapeutic promise of retatrutide by granting it designations that could expedite review (e.g. it may qualify for Fast Track status given its first-in-class nature and the magnitude of benefit seen). Still, until Phase 3 data are available, retatrutide remains experimental. As of November 2025, clinicians can only access it through clinical trials. Given the intense interest, analysts predict that if Phase 3 mirrors Phase 2 results, Lilly could file a New Drug Application by 2026, and retatrutide could potentially be approved for obesity (and possibly diabetes) by 2027. In the interim, some patients have sought retatrutide through off-label or compounded means, but regulators (like FDA) have warned against using unapproved research drugs outside trials. In summary, retatrutide is on track in its development timeline, but healthcare providers and patients will have to await completion of trials and regulatory review before it becomes an available therapy.

Comparisons with Semaglutide and Other GLP-1 Agonists

Semaglutide (a selective GLP-1 receptor agonist) is the current benchmark therapy for both type 2 diabetes and obesity, so it serves as a useful comparator for tirzepatide and retatrutide:

• Mechanistic Differences: Semaglutide (Ozempic for diabetes, Wegovy for obesity) acts only on the GLP-1 receptor. Tirzepatide targets both GLP-1 and GIP receptors (“dual agonist”), while retatrutide targets GLP-1, GIP, and glucagon receptors (“triple agonist”). These additional targets likely explain the enhanced efficacy of tirzepatide/retatrutide. GIP co-agonism (unique to tirzepatide and retatrutide) may further stimulate insulin release and modulate appetite beyond GLP-1 alone, and as discussed, may improve tolerability. Glucagon receptor agonism (unique to retatrutide) adds a mechanism to increase energy expenditure and promote fat burning. Thus, retatrutide has the broadest mechanism among the three, which appears to translate into the greatest weight loss effect.
• Weight Loss Efficacy: Semaglutide 2.4 mg weekly leads to ~15% average body weight reduction in 68 weeks (Wilding et al., 2021) – a degree that made it the most effective obesity drug until now. Tirzepatide, in a head-to-head context, has demonstrated even greater weight loss. In an indirect comparison, adults with obesity on tirzepatide 15 mg lost ~21% by 72 weeks (Jastreboff et al., 2022) whereas those on semaglutide 2.4 mg lost ~15% by 68 weeks[19]. A direct comparison in diabetics (SURPASS-2) found tirzepatide 15 mg caused an extra 5.5 kg weight loss vs. semaglutide 1 mg over 40 weeks[8]. Retatrutide thus far has only indirect comparisons, but its ~24% weight reduction at 48 weeks (Jastreboff et al., 2023) is dramatically higher than what semaglutide achieved at the similar 48-week mark in earlier studies (~12% at 48 weeks in STEP trials). It is plausible that over 72+ weeks, retatrutide could approach 30% weight loss on average, something semaglutide likely cannot reach in most patients. In short, retatrutide appears to be roughly 1.5× more potent for weight loss than semaglutide, and tirzepatide is intermediate – perhaps ~1.2–1.3× more potent than semaglutide (comparing highest tolerated doses).
• Glycemic Control: In type 2 diabetes, semaglutide is among the most effective current drugs, lowering HbA_1c by ~1.5–1.8% and often inducing remission of diabetes in high responders. Tirzepatide and retatrutide have shown even greater reductions (up to ~2.0–2.3%). The SURPASS-2 trial established tirzepatide's superiority over semaglutide for glycemic endpoints (Frías et al., 2021), and retatrutide in Phase 2 likewise surpassed dulaglutide (a GLP-1 RA similar to semaglutide) (Rosenstock et al., 2023). Practically, all three agents can normalize blood sugar in many patients, but the dual/triple agonists may achieve target HbA_1c levels in a higher proportion of patients and more rapidly. Another consideration is durability of control – ongoing studies will reveal if multi-agonists maintain glycemic targets longer or with less adjunctive therapy than GLP-1 alone.
• Safety and Tolerability: All three drugs share the common GI side effects of nausea, vomiting, and diarrhea. Comparatively, semaglutide's tolerability profile is well-characterized: about 44% of patients on semaglutide 2.4 mg report nausea, and ~5% discontinue due to GI issues (Wilding et al., 2021[21]). Tirzepatide at 15 mg had a similar GI profile; in some studies, nausea rates were a bit lower than with semaglutide, but diarrhea was slightly more frequent – overall GI event rates are in the same ballpark (Frías et al., 2021; Jastreboff et al., 2022). Retatrutide at high dose showed higher rates of transient nausea (~60–70% of patients) but this was managed with dose titration; the dropout rate due to GI effects was still only around 7–9% (Jastreboff et al., 2023). Thus, tolerability might be marginally more challenging with retatrutide if not carefully titrated, due to the very potent effect (which can cause rapid appetite suppression and weight loss). However, when comparing across trials, all these agents require titration and patient counseling for GI symptoms.

One area of difference is potential additional side effects: semaglutide and tirzepatide are not known to cause any significant effects beyond GI, whereas retatrutide's glucagon activity raises considerations like slight tachycardia and possibly mild elevations in liver enzymes initially (though ultimately liver fat decreases). Retatrutide's triple action means it should be used with caution in patients where even mild glucagon-like effects (e.g. transient hyperglycemia if a meal is skipped, or slight blood pressure increases) could be an issue, although in trials its net effect was blood pressure reduction and glucose lowering due to dominant GLP-1/GIP actions.

• Cardiovascular Outcomes: GLP-1 RAs like semaglutide have demonstrated cardiovascular benefit in outcome trials (semaglutide reduced 3-point MACE by ~26% in the recent SELECT trial in obesity, and showed a 27% CV risk reduction in diabetics with high risk in SUSTAIN-6/EMA). Tirzepatide's CV outcome trial is underway, but given its greater weight and glycemic effects, many expect it to confer at least similar if not greater cardioprotection. Early real-world evidence suggests favorable trends (Sattar et al., 2022). Retatrutide will also be evaluated for CV outcomes (TRIUMPH-3 is focusing on obese patients with established cardiovascular disease). Therefore, while semaglutide currently has the advantage of proven CV risk reduction, tirzepatide and retatrutide may match or exceed this once data become available.
• Practical Use and Dosing: Semaglutide and tirzepatide are both once-weekly subcutaneous injections. Retatrutide will also be weekly. Semaglutide comes as a pre-filled pen; tirzepatide similarly. Patient experiences with injections are likely comparable among them. One difference is dosing flexibility: semaglutide for obesity has a fixed 2.4 mg target (with a set titration schedule), whereas tirzepatide is available in multiple dose strengths (5, 10, 15 mg) and clinicians can adjust the dose based on tolerability and response. This flexibility might allow more personalized dosing with tirzepatide (some patients might do well on 10 mg and avoid extra side effects of 15 mg, for example). Retatrutide's development will reveal an optimal dose – Phase 2 suggests 10 mg or 12 mg may be the target maintenance dose for obesity, but dose-ranging is still under investigation.

In conclusion, when comparing these advanced therapeutics: semaglutide is highly effective but appears to be outperformed by tirzepatide in both weight loss and glycemic control, and retatrutide in turn has shown even greater efficacy in early trials. All require injection and have similar safety profiles dominated by GI effects. The advent of tirzepatide and retatrutide represents a significant leap forward, building on the success of GLP-1 agonists like semaglutide. For patients and providers, this means more powerful tools to treat obesity and diabetes, possibly converting these chronic conditions into much more manageable ones or inducing remission. As always, the choice of therapy will depend on individual patient factors (comorbidities, tolerance, access), but the competition is a positive for medical progress. Semaglutide set the stage as a game-changer, and tirzepatide and retatrutide are now pushing the boundaries even further in metabolic disease treatment.

Conclusion

Tirzepatide and retatrutide exemplify the next generation of metabolic medications, leveraging multi-hormone pathways to produce unprecedented outcomes. Tirzepatide's dual GIP/GLP-1 mechanism has translated into superior glycemic control and substantial weight loss in clinical trials, leading to approvals for both T2DM and obesity. Retatrutide's triple agonist approach has delivered astonishing Phase 2 results, with weight loss around 24% in 48 weeks – establishing a new efficacy benchmark and offering hope for tackling conditions like NAFLD alongside obesity and diabetes. Both agents significantly improve metabolic health parameters, potentially reducing cardiovascular and liver-related risks. Safety profiles are manageable and similar to established GLP-1 therapies, with gastrointestinal side effects being the main consideration. Regulatory momentum is strong: tirzepatide is now in clinical use for multiple indications, and retatrutide is progressing through Phase 3 with much anticipation. In comparison to semaglutide, these newer therapies provide greater potency, which could benefit patients who need more aggressive weight or glucose reductions. It is an exciting era in which pharmacological treatment of obesity and diabetes is becoming as effective as surgery for some patients. Ongoing research will elucidate long-term outcomes, optimal use combinations, and any unforeseen effects. For now, the emerging evidence positions tirzepatide and retatrutide as powerful tools that may fundamentally reshape the management of metabolic diseases, offering improved quality of life and health outcomes for millions of patients.

References:

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., & Bergman, B. K., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., & Connery, L., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., & Gurbuz, S., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
4. Rosenstock, J., Frías, J. P., Jastreboff, A. M., Du, Y., Haupt, A., & Milicevic, Z., et al. (2023). Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Phase 2 Trial. The Lancet, 402(10350), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
5. Sanyal, A. J., Kaplan, L. M., Frías, J. P., Brouwers, B., Wu, Q., & Hartman, M. L., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(10), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2
6. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., & Lingvay, I., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
7. Corrao, S., Pollicino, C., Maggio, D., Torres, A., Argano, C., et al. (2024). Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Frontiers in Endocrinology, 15, Article 1402583. https://doi.org/10.3389/fendo.2024.1402583
8. Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025). Retatrutide – A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796. https://doi.org/10.3390/biom15060796
9. Drucker, D. J. (2022). Twincretin Power: Triaging Glucose Control and Weight Loss. Cell Metabolism, 35(3), 529–531. https://doi.org/10.1016/j.cmet.2022.02.013
10. Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., & Wiese, R. J., et al. (2022). Tirzepatide for the Treatment of Obesity: A Multidisciplinary Viewpoint. Diabetes, Obesity and Metabolism, 24(8), 1508–1512. https://doi.org/10.1111/dom.14751

[1] [3] Frontiers | Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1402583/full

[2] [4] [8] Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

https://www.darmzentrum-bern.ch/fileadmin/darmzentrum/Education/Journal_Club/2022/JC-22-01-19__Tirzepatid.Surpass2.NEJM.2021.pdf

[5] [17] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial | Nature Medicine

https://www.nature.com/articles/s41591-024-03018-2?error=cookies_not_supported&code=5180d9d3-d675-4442-9dd6-b1ec093f8109

[6] [7] [15] [16] [18] Retatrutide—A Game Changer in Obesity Pharmacotherapy - PMC 

https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

[9] [10] [11] [12] [22] [25] Tirzepatide Once Weekly for the Treatment of Obesity - PubMed

https://pubmed.ncbi.nlm.nih.gov/35658024/

[13] [14] [23] [24] [26] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial - PubMed

https://pubmed.ncbi.nlm.nih.gov/37366315/

[19] [20] [21] Once-Weekly Semaglutide in Adults with Overweight or Obesity - PubMed

https://pubmed.ncbi.nlm.nih.gov/33567185/